Harrow is an eyecare-focused pharmaceutical company that commercializes branded and compounded ophthalmic medicines for eye-care professionals and patients in North America. Its portfolio covers essential eye therapies and a specialized compounding arm (including ImprimisRx) aimed at accessible, high-value treatments. The business concentrates exclusively on ophthalmology rather than broad-spectrum pharmaceuticals.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 47.8 | — | -17.8 | — |
| Q2 2025 | 63.7 | — | 5 | — |
| Q3 2025 | 71.6 | — | 1 | — |
| Q4 2025 | 89.1 | — | 6.6 | — |
| Q1 2026 | 44.2 | -7.6% | -27.6 | — |
| Q2 2026 | 70.7 | 10.8% | -17.3 | -445.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Oaktree Specialty Lending Corporation (OCSL), Business First Bancshares, Inc. (BFST), Green Plains Inc. (GPRE), HealthStream, Inc. (HSTM), Mercantile Bank Corporation (MBWM), CNB Financial Corporation (CCNE)